Clinical Trials Logo

Clinical Trial Summary

This clinical trial collects information on how sequencing a patient's deoxyribonucleic acid (DNA) (i.e., the genetic material) could impact their health care. This study also develops and improves ways to include genomic information from DNA sequencing into the electronic health record to create a more complete "Health Tapestry" for each participant. Sequencing of a patient's DNA leads to the detection of genetic variants some of which determine risk for disease development. Discovery of those genetic variants in a patient could result in prevention, earlier diagnosis or better therapy of disease.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To detect and compare the actionable genetic findings derived from whole exome sequencing (WES) testing and examine their frequency and association with family history using a large cohort of patients seen across specialties within the Mayo Clinic enterprise. II. To assess the effect of actionable genetic findings of patients on health-care utilization, and patients acceptance. III. To create a unique vertically integrated data asset (Mayo Clinic Health Tapestry) that links genomics and other omics information to traditional health parameters in the Electronic Medical Record (EMR) with the aim to elucidate disease formation and outcomes. IV. Assess the frequency of hereditary cancer predisposition genes (BRCA1, BRCA2, Lynch syndrome mismatch repair [MMR] genes) through population screening using WES and the uptake of genetic counseling. V. To study the genetic predisposition to coronavirus disease 2019 (COVID-19) disease we propose using a COVID-19 survey. OUTLINE: Participants receive a saliva kit, register with Helix then undergo collection of saliva sample which is returned o Helix. Participants also receive an online link to complete the About Me family history. Once sequencing is completed by Helix, ancestry/trait information and genetic findings are shared with participants and their primary provider, if applicable. Participants with positive results are offered genetic counseling and are encouraged to seek clinical confirmatory testing. Following clinical confirmation, results are scanned into the electronic health record. Participants may also undergo the collection of blood, urine, and stool samples for future studies. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05212428
Study type Interventional
Source Mayo Clinic
Contact
Status Recruiting
Phase N/A
Start date January 8, 2020
Completion date December 31, 2026

See also
  Status Clinical Trial Phase
Completed NCT01734486 - Growth Response in Girls With Turner Syndrome Phase 4
Completed NCT01529944 - Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658 Phase 3
Completed NCT01518036 - Use of Somatropin in Turner Syndrome Phase 3
Completed NCT00025870 - Studies of Children With Metabolic and Other Genetic Disorders
Completed NCT01563926 - Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Phase 3
Active, not recruiting NCT01851447 - Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy
Completed NCT01435629 - A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin N/A
Completed NCT01245374 - Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Phase 4
Terminated NCT01135537 - Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants Phase 2
Completed NCT00705172 - Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome N/A
Completed NCT01518062 - Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Phase 4
Recruiting NCT02769949 - Pediatric Patients With Metabolic or Other Genetic Disorders
Terminated NCT00358657 - Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders Phase 2
Completed NCT01604161 - Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome N/A
Completed NCT01516229 - Special Survey for Long Term Application N/A
Recruiting NCT03093220 - Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis N/A
Completed NCT01529840 - Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome Phase 3
Completed NCT01710696 - Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome Phase 3
Completed NCT01401244 - Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers Phase 1
Completed NCT01517048 - Brain-Derived Neurotrophic Factor in Obesity and Brain Function